Five-year follow-up study of imlifidase in kidney transplantation garners “positive” outcomes

Hansa Biopharma has announced the presentation of its five-year extended pooled analysis including data from the 17-HMedIdeS-14 study, an international long-term follow-up study of patients who have received a kidney transplant following desensitisation with imlifidase at the 2025 International Transplant Congress of the European Society for Organ Transplantation (ESOT 29 June–2 July, London, UK).

Massimo Mangiola (NYU Langone Transplant Institute, New York, USA) presented the outcomes of the extended pooled analysis including data from the 17-HMedIdeS-14 study, presented at the American Transplant Congress (ATC) 2024, and published as a letter to the editor in the American Journal of Transplantation.

The extended pooled analysis, including data from the 17-HMedIdeS-14 study, showed sustained positive outcomes out to five years of highly sensitised patients who received an imlifidase-enabled kidney transplant.

After five years, the patient survival rate was 90% (reflecting three deaths occurring between six months and one year) and graft survival (death censored) was 82%, in line with outcomes seen at three-years. At five years, mean estimated glomerular filtration rate (eGFR) or kidney function was 50 mL/min/m² in the imlifidase treated patients.

eGFR is a measure of how well the kidneys are working in the body—higher eGFR indicates better kidney function. For many kidney transplant recipients three years post-transplant the mean eGFR is anywhere between 40–60 ml/min per 1.73m² with continued decline of eGFR function at five years post-transplant.

Hitto Kaufmann, chief research & development officer, Hansa Biopharma, said: “We are very pleased to see that the 17-HMedIdeS-14 extended pooled analysis data continue to excite the clinical community. This study demonstrated for the first time that HLA-incompatible transplantation following desensitisation with imlifidase is a viable option for patients who need it, with long term benefit comparable to standard kidney transplants, providing a life changing alternative to remaining on dialysis.”